Skip to main content

Table 1 Demographic, clinical and pathological features of the patients included in the study

From: Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach

Characteristics Global cohort (41 cases) Discovery cohort (30 cases) Validation cohort (11 cases) p-value
Male sex, n (%) 28 (68.3) 15 (53.6) 11 (100) 0.003
Age, (mean ± SD), years 55 ± 12.7 53.9 ± 13.2 58 ± 11.1 0.324
IPMD, (mean ± SD), months 24.3 ± 26.4 25.3 ± 29.2 21.1 ± 13.4 0.523
Melanoma type, n (%)
 NM 12 (29.3) 8 (26.7) 4 (36.4) 0.828
 SSM 28 (68.3) 21 (70) 7 (63.6) 0.993
 LMM 1 (2.4) 1 (3.3) 0 (0) 1.000
Melanoma site, n (%)
 A. Primitive
  Head 2 (4.9) 2 (6.7) 0 (0) 1.000
  Neck 3 (7.3) 2 (6.7) 1 (9.1) 1.000
  Trunk 19 (46.3) 13 (43.3) 6 (54.5) 0.776
  Upper limbs 3 (7.3) 2 (6.7) 1 (9.1) 1.000
  Lower limbs 14 (34.1) 11 (36.7) 3 (27.3) 1.000
 B. Metastasis 49 (100) 36 (73.5) 13 (26.5) 0.853
  Lymph nodes 31 (64.6) 23 (63.9) 8 (66.7)
  Visceral 18 (35.4) 13 (36.1) 5 (33.3)
Number of mitosis per smm (mean ± SD) 3.4 ± 3.1 4.1 ± 3.0 1.6 ± 2.5 0.003
Breslow thickness, (mean ± SD) 3.8 ± 2.4 4.0 ± 2.4 3.2 ± 1.4 0.566
Ulceration, n (%) 18 (43.9) 12 (40) 6 (54.5) 0.634
Initial T/N stage, n (%)
 A. T stage
  T1 2 (4.9) 2 (6.7) 0 1.000
  T2 7 (17.1) 5 (16.7) 2 (18.2) 1.000
  T3 19 (46.3) 13 (43.3) 6 (54.5) 0.776
  T4 13 (31.7) 10 (33.3) 3 (27.3) 1.000
 B. N stage
  N0 8 (19.5) 6 (20.0) 2 (18.2) 1.000
  N1 16 (39.0) 11 (36.7) 5 (45.4) 0.723
  N2 13 (31.7) 9 (30.0) 4 (36.4) 1.000
  N3 4 (9.8) 4 (13.3) 0 0.559
  1. Significant p-values are indicated in italics
  2. IPMD interval progression of metastatic disease, LMM lentigo maligna melanoma, NM nodular melanoma, SD standard deviation, SSM superficial spreading melanoma